updated 11/16/2010 8:17:22 AM ET 2010-11-16T13:17:22

HAIFA, Israel, Nov. 16, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today reported that the company will present two key aspects of its clinical trials -- quality and regulatory, at the Commercial Translation of Regenerative Medicine Conference in London, UK. Mrs. Chaya Mazouz, Pluristem's VP Clinical and Regulatory Affairs, will participate in a panel discussion, titled "Validatory pathways to optimize cell product quality." In addition, Mrs. Mazouz will present a case study which outlines the organization transformation needed from Phase I to commercialization. The conference will take place on November 18-19, 2010.

"We are proud that Mrs. Mazouz was invited to present Pluristem's approach for converting a novel idea of cell therapy to a product that may help millions of PAD patients," said Zami Aberman, Chairman and CEO of Pluristem. "Mrs. Mazouz will also present Pluristem's unique approach to conducting 2 Phase I clinical studies under the approval of the FDA and the Paul Ehrlich Institute (PEI), the German regulatory authority for advanced therapy products (ATP)."

CLICK HERE to watch CLI Patients and Doctors Involved in Trials Sharing Their Stories on Video, the content of which is not part of this press release.

About Pluristem

Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.

The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we say that we will discuss the idea of converting a novel idea of cell therapy to a product that may help millions of PAD patients. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our Web site at www.pluristem.com , the content of which is not part of this press release.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com